Efficacy and safety of Shenfu injection in the treatment of sepsis
A protocol for systematic review and meta-analysis
Shu Luo, MB\textsuperscript{a}, Lianping Gou, MB\textsuperscript{b}, Shiping Liu, MB\textsuperscript{b}, Xiaoping Cao, MB\textsuperscript{a},* \textsuperscript{10}

Abstract

Background: Sepsis is a syndrome of infection-induced systemic inflammatory response. Conventional treatment combined with Shenfu injection (SFI) has been previously validated clinical effective in alleviating inflammatory response in patients with septic shock. However, evidence-based medical evidence is scant. Herein, we designed the protocol of a proposed study based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aiming to systematically evaluate the efficacy and safety of SFI in patients with sepsis.

Methods: Eligible studies reporting the efficacy and safety of SFI in the treatment of sepsis published before August 2021 will be searched from online databases, including the PubMed, Web of Science, EMBASE, Ovid, the Cochrane Library, Wanfang Database, China National Knowledge Infrastructure, and China Biology Medicine Disc. The literature selection process will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. After data extraction and methodological quality evaluation, Stata 12.0 software will be used to synthesize the data through fixed/random effects of meta-analysis models.

Results: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication.

Conclusion: This study will provide reliable evidence-based basis for the clinical application of SFI in the treatment of sepsis.

OSF Registration number: DOI 10.17605/OSF.IO/KCMDQ.

Abbreviations: SFI = Shenfu injection, TCM = traditional Chinese medicine.

Keywords: meta-analysis, protocol, sepsis, Shenfu injection

1. Introduction

Sepsis is a systemic inflammatory response caused by infection, which is a common critical illness.\textsuperscript{[1,2]} It is estimated there are more than 1.8 million patients with severe sepsis worldwide each year.\textsuperscript{[3]} Sepsis is featured by the rapid progression and has high mortality, which can be as high as 80% in sepsis complicated with infectious shock. As a result, sepsis is one of the major causes of death in critically ill patients.\textsuperscript{[3]} Therefore, the treatment of sepsis has been a hot spot in clinical research.

The development of sepsis is closely related to the release of inflammatory mediators from the human bodies, the spread or translocation of bacterial endotoxins, and coagulation disorders.\textsuperscript{[4,5]} Sepsis can further develop into septic shock (infectious shock).\textsuperscript{[6]} Septic shock is a syndrome of sepsis with severe cellular, metabolic and circulatory disturbances, and its risk of death is significantly higher than that of sepsis alone.\textsuperscript{[7]} As a major event during the disease process, the inflammatory response produces a cascade of waterfall reactions alongside the release of abundant inflammatory factors, and organ dysfunction occurs in severe cases.\textsuperscript{[8]} It is suggested that the inflammatory response is an important factor for the occurrence of septic shock.\textsuperscript{[9]} Currently, the conventional treatments of septic shock, including fluid resuscitation, anti-infection, anticoagulation, administration of vasoactive drugs and glucocorticoids, are important to stabilize blood pressure and reduce the inflammatory response.\textsuperscript{[10–12]} However, they are supportive management that cannot target the individualized cause of sepsis. About 1/3 of patients with sepsis do not have a clear clue of pathogenic bacteria.\textsuperscript{[13]} Therefore, it is urgent to propose new treatment options for sepsis.
Traditional Chinese medicine (TCM) believes that sepsis belongs to the category of heat illness in typhoid and warm diseases, and it may also be related to Wei, Qi, Ying, and Blood. The basic pathogenesis of septemia is the imbalance of the internal organs due to the deficiency of the root and the prevalence of evil. Therefore, the TCM theory highlights the support of root cause in the treatment of sepsis. Shenfu injection (SFI) is derived from the ancient formula Shenfu decoction, which mainly contains the TCM herbs ginseng and radix aconiti carmichaeli. Ginseng has the effect of strengthening the vital energy, restoring the pulse and fixing the detachment, tonifying the spleen and benefitting the lung, generating fluid and quenching thirst, and calming the mind and educating the mind. Radix aconiti carmichaeli has the effect of returning Yang to rescue the rebellion, tonifying heat and helping Yang, dispersing cold and relieving pain. Through benefiting Qi and returning Yang, SFI strengthens the positive energy and enhances organ functions.

SFI is mainly composed of ginsenosides, aconitine, and other active ingredients, which have strong effects on maintaining blood pressure, stabilizing heart rate, and reducing pathological damage. It is confirmed that SFI combined with glucocorticoids can improve the immune function and reduce the level of inflammatory factors in patients with severe sepsis. Numerous studies have validated the function of SFI in improving the prognosis of sepsis, but controversy remains and evidence-based medical evidence is scant. This study aims to provide evidence-based medical evidence for the efficacy and safety of SFI in the treatment of sepsis through a systematic review and meta-analysis.

2. Methods

2.1. Protocol registration

This protocol was registered on the open science framework (Registration Number: DOI 10.17605/OSF.IO/KCMDQ). We will strictly perform this protocol by following the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols statement guidelines.

2.2. Inclusion criteria for study selection

2.2.1. Type of studies. Only randomized controlled trials about SFI for the treatment of sepsis will be included, and publication language will be limited in English or Chinese, and blinding method will not have a restriction.

2.2.2. Type of participants. All patients with sepsis will be included without limitation of the age, race, and disease severity.

2.2.3. Type of interventions

2.2.3.1. Experimental interventions. Experimental interventions will include conventional treatment combined with intravenous administration, intravenous drip or intramuscular administration of SFI. The dose and frequency of SFI administration will be unlimited.

2.2.3.2. Control interventions. Control interventions will involve conventional treatments like fluid resuscitation, anti-infection, anticoagulation, vasoactive drugs, and glucocorticoids.

2.2.4. Type of outcome measures

2.2.4.1. Primary outcomes. The 28-day mortality.

2.2.4.2. Additional outcomes.

1. Total effective rate;
2. Length of ICU stay;
3. Acute physiology and chronic health evaluation II;
4. Inflammatory indicators, including tumor necrosis factor-α (TNFα), serum procalcitonin (PCT), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), etc; and
5. Adverse events.

2.3. Exclusion criteria

1. Retrospective studies, and
2. Studies with incomplete important information.

2.4. Searching strategy

A systematic searching of relevant literatures reporting the efficacy and safety of SFI in the treatment of sepsis published before August 2021 in PubMed, Web of Science, EMBASE, Ovid, the Cochrane Library, Wanfang Database, China National Knowledge Infrastructure, and China Biology Medicine Disc will be performed. The searching strategies in the PubMed were shown in Table 1, which will be used in other online databases. Literatures will be limited in Chinese and English language, without restriction on publication status.

| Number | Search terms |
|--------|--------------|
| #1     | Sepsis[MeSH] |
| #2     | Pyaemia[Title/Abstract] |
| #3     | Pyemia[Title/Abstract] |
| #4     | Pyemia[Title/Abstract] |
| #5     | Blood poisoning[Title/Abstract] |
| #6     | Poisoning, blood[Title/Abstract] |
| #7     | Septicemia[Title/Abstract] |
| #8     | Severe sepsis[Title/Abstract] |
| #9     | Blood poisonings[Title/Abstract] |
| #10    | Poisonings, blood[Title/Abstract] |
| #11    | Pyaemia[Title/Abstract] |
| #12    | Pyemia[Title/Abstract] |
| #13    | Pyoesthesias[Title/Abstract] |
| #14    | Sepsis, severe[Title/Abstract] |
| #15    | Septicemia[Title/Abstract] |
| #16    | ORV1 to 15 |
| #17    | Shenfu injection[Title/Abstract] |
| #18    | Randomized controlled trials as topic[MeSH] |
| #19    | Clinical trials, randomized[Title/Abstract] |
| #20    | Controlled clinical trials, randomized[Title/Abstract] |
| #21    | Trials, randomized clinical[Title/Abstract] |
| #22    | Random* [Title/Abstract] |
| #23    | ORV18 to 22 |
| #24    | #16 and #17 and #23 |
2.5. Study selection and data extraction

2.5.1. Selection of studies. A Preferred Reporting Items for Systematic Reviews and Meta-analysis flow chart will be drawn to illustrate the study selection procedure (Fig. 1). According to the research objectives and inclusion criteria, 2 researchers will independently read the literatures and extract data. Any disagreement will be solved by discussing with the third researcher.

2.5.2. Data extraction and management. The following data will be extracted:

1) Literature source and publication date of the study title,
2) Age of subjects in experimental group and the control group, intervention measures and the implementation of the experiment,
3) Study type and relevant elements of bias risk assessment, and
4) Outcome indicators and outcomes.

2.5.3. Risk of bias in the included studies. Two researchers will independently evaluate the risk of bias for each study using the Cochrane Collaboration tool, including random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias. Each domain will be ranked as low risk of bias, high risk of bias or unclear risk of bias.

2.5.4. Measures of treatment effects. For dichotomous outcomes, risk ratio will be used in the meta-analysis. For continuous variables, the standardized mean difference with 95% confidence intervals will be selected. All of these data will be analyzed with the corresponding 95% confidence intervals.

2.5.5. Dealing with missing data. Insufficient or missing data in the literature will be required by e-mailing the authors. If not available, only the current available data will be analyzed and the potential impacts will be discussed.

2.5.6. Assessment of heterogeneity. Heterogeneity will be tested by Q-statistic and I^2-statistic. I^2 > 50% will be considered as significant heterogeneity, and the random-effects model or the fixed-effects model will be adopted.
2.5.7. **Data synthesis and meta-analysis.** Stata 12.0 software (STATA Corporation, College Station, TX) will be used to combine and calculate the outcomes. If the heterogeneity is not significant ($P > .1$ or $I^2 < 50\%$), the fixed effect model will be adopted; Otherwise ($P < .1$ or $I^2 \geq 50\%$), the random effect model will be chosen. Two-tailed $P < .05$ indicates statistical significances.

2.5.8. **Subgroup analysis.** Subgroup analyses based on the dose of SFI, treatment durations and different types of routes of administration will be performed.

2.5.9. **Sensitivity analysis.** Sensitivity analyses will be performed by removing the studies with high risk of bias or missing data.

2.5.10. **Assessment of publication bias.** Publication bias will be assessed by depicting funnel plots if a sufficient number of trials (more than 10) are included.

2.5.11. **Ethics and dissemination.** Since the program does not include the recruitment of patients and the collection of personal information, it does not require the approval of the Ethics Committee.

3. Discussion

Sepsis is a common critical clinical condition with a high mortality. Although anti-inflammatory drugs and immune-enhancing agents like glucocorticoids and thymidine alpha 1 have been widely used in clinical practice, their adverse effects are becoming increasingly prominent. In recent years, with the continuous development of clinical research, TCM treatment of sepsis has been widely recognized. Among them, SFI has been frequently used in the treatment of sepsis because of its effect on returning Yang and rescuing the rebellion, and supporting the righteousness and fixing the detoxification. Although the therapeutic effectiveness of SFI for sepsis has been reported, evidence-based medical evidence is lacking. This meta-analysis will provide a detailed summary and analysis of the most recent evidence. We hope that our findings will help patients, clinicians, and healthcare policy makers to develop optimal TCM treatment options for patients with sepsis.

**Author contributions**

Conceptualization: Xiaoping Cao, Shu Luo.

Data curation: Shu Luo, Lianping Gou.

Formal analysis: Xiaoping Cao, Shu Luo.

Investigation: Lianping Gou.

Methodology: Lianping Gou.

Resources: Lianping Gou.

Software: Shiping Liu.

Supervision: Xiaoping Cao.

Validation: Shiping Liu.

Visualization: Shiping Liu.

Writing – original draft: Xiaoping Cao, Shu Luo.

Writing – review & editing: Xiaoping Cao, Shu Luo.

**References**

[1] Randolph JL, Chan K, Albright A, Chen A. Delays in administration of the second antibiotic dose in patients with severe sepsis and septic shock. Hosp Pharm 2021;56:247–51.

[2] Shen G, He Y, Ni J, et al. Effects of comprehensive nursing on negative emotion and prognosis of patients with sepsis. Am J Transl Res 2021;13:8221–7.

[3] Zhang W, Duan D, Zhang Z, et al. Influence of Shenfu injection combined with low molecular weight heparin on serum NT-ProBNP, cystatin C, coagulation function and prognosis in children with pneumonia. China J Mod Med 2017;27:61–5.

[4] Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med 2020;46:1532–62.

[5] Wang J, Sun Y, Teng S, Li K. Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation. BMC Med 2020;18:83.

[6] Fong KM, Au SY, Ng GWY. Steroid, ascorbic acid, and thiamine in adults with sepsis and septic shock: a systematic review and component network meta-analysis. Sci Rep 2021;11:13777.

[7] Rather AR, Kasana B. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). J Med Sci 2015;18:162–4.

[8] He WT, Wan H, Hu L, et al. Gauderman D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res 2015;25:1285–98.

[9] Yang J, Yang Y, Liu Q. Early levels of major inflammatory factors in patients with septic shock and their clinical significance. Chin Crit Care Med 2019;31:680–3.

[10] Sepsis recognition, diagnosis and early management: © NICE (2017).

[11] BJU Int 2018;121:497–514.

[12] Teng CH, Chen TT, Wu MY, Chan MC, Shih MC, Tu YK. Resuscitation fluid types in sepsis, surgical, and trauma patients: a systematic review and sequential network meta-analyses. Crit Care (London, England) 2020;24:693.

[13] Snow TAC, Littlewood S, Corredor C, Singer M, Arulkumaran N. Effect of extracorporeal blood purification on mortality in sepsis: a meta-analysis and trial sequential analysis. Blood Purif 2021;50:462–72.

[14] Wei Y, Kuang J, Chen Y. Detection and analysis of pathogenic bacterial infections, risk factors, and related immune and inflammatory indexes in patients with sepsis. J Pathog Biol 2019;14:94–7.

[15] Wang X, Chen T, Luo D, Zhang N, Lv X, Liu Q. Analysis of TCM pathogenesis of septic shock based on different syndrome differentiation system. J Emerg Tradit Chin Med 2018;27:101–4.

[16] Jiang T, Bai X, Wen N, et al. Research progress of traditional Chinese medicine ginseng in the treatment of sepsis. China J Tradit Chin Med 2019;36:3495–9.

[17] Zeng D. Progress in pharmacological research and clinical application of ShenFu injection. Res Integr Tradit Chin Med 2019;011:159–61.

[18] Li M, Pan T, Yu T, Zhao J, et al. Mechanism of Shenfu injection in the treatment of sepsis based on network pharmacology. Shandong Sci 2021;1:19.

[19] Yang H, Liu L, Gao W, Liu K, Qi I, Li P. Direct and comprehensive analysis of ginsenosides and diterpene alkaloids in Shenfu injection by combinatorial liquid chromatography–mass spectrometric techniques. J Pharm Biomed Anal 2014;92:13–21.

[20] Hwa JB, Seong KG, Hoo-Suk K, Jion-Bong P, Yeul NK, Chang SJ. Effect of Korean red ginseng on blood pressure and nitric oxide production. Acta Pharmacol Sin 2000;21:1095–100.

[21] Chen XW, Fu J, Ruan XM. Effects of Shenfu injection on immune function in patients during perioperative cardiopulmonary bypass. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006;26:775–9.

[22] Wang X, Li J, Li Z, et al. Effects of Shenfu injection combined with glucocorticoid on PCT, NT-proBNP and inflammatory factors in patients with sepsis. J Emerg Tradit Chin Med 2019;28:954–7.

[23] Li M, Pan T, Lyu L, et al. Effect of traditional Chinese medicine syndrome differentiation and standard bundle therapy in patients with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2019;31:852–5.

[24] Zhang N, Liu J, Qu S, Ye Y, Zhang J, Lou T. Shenfu injection for improving cellular immunity and clinical outcome in patients with severe sepsis and septic shock. Am J Emerg Med 2017;35:1–6.

[25] Cui ZL, Ye YP, Zhang N. Clinical efficacy of Shenfu injection in treating severe sepsis and its effects on serum levels of interleukin-6 and interleukin-10. Zhongguo Zhong Xi Yi Jie He Za Zhi 2012;32:348–51.

[26] Lai G. Effects of the Shenfu injection plus ulinastatin on inflammatory cytokines, coagulation function and prognosis in sepsis patients. Clin J Chic Med 2018;10:13–5.

[27] Yuan C, Jin N. Clinical effect of Shenfu injection combined with liquid resuscitation on sepsis. World J Integr Tradit West Med 2020;15:25–9.
[27] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.

[28] Irwig L, Macaskill P, Berry G, Glasziou P. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ 1998;316:470.

[29] Zhao G, Guo Y, Li B, et al. Research progress of traditional Chinese medicine in prevention and treatment of sepsis. Zhongguo Zhong Yao Za Zhi 2017;42:1423–9.

[30] Chai R, Lu J, Zhao Y, Lv X, Yu Y, Chen X. Research progress on Chinese medicine injection in the prevention and treatment of sepsis. China J Tradit Chin Med Pharm 2019;34:2617–9.